​

Candel Therapeutics (CADL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CADL Stock Rating

Candel Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

CADL Price Target Upside V Benchmarks

TypeNameUpside
StockCandel Therapeutics-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$5.36$5.36$5.36
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25-3---3
May, 2513---4
Apr, 2513---4
Mar, 2513---4
Feb, 251----1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 18, 2024H.C. WainwrightBuyBuyhold
Dec 07, 2022Credit SuisseOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-1.26$-0.10$-1.31$-1.74--
Avg Forecast$-2.01$-0.70$-1.09$-1.59$-1.35$0.09
High Forecast$-2.01$-0.70$-1.09$-1.59$-1.35$0.09
Low Forecast$-2.01$-0.70$-1.09$-1.59$-1.35$0.09
Surprise %-37.31%-85.71%20.18%9.43%--

Revenue Forecast

$0 $19M $38M $57M $76M $95M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$125.00K$125.00K----
Avg Forecast$33.00K$81.25K$15.50K$15.50K$4.35M$92.50M
High Forecast$33.00K$81.25K$15.50K$15.50K$4.35M$92.50M
Low Forecast$33.00K$81.25K$15.50K$15.50K$4.35M$92.50M
Surprise %278.79%53.85%----

Net Income Forecast

$-60M $-47M $-34M $-21M $-8M $5M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-36.18M$-2.87M$-37.94M---
Avg Forecast$-58.20M$-20.12M$-31.54M$-46.01M$-39.06M$2.60M
High Forecast$-58.20M$-20.12M$-31.54M$-46.01M$-39.06M$2.60M
Low Forecast$-58.20M$-20.12M$-31.54M$-46.01M$-39.06M$2.60M
Surprise %-37.84%-85.76%20.29%---

CADL Forecast FAQ

Is Candel Therapeutics stock a buy?

Candel Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Candel Therapeutics is a favorable investment for most analysts.

What is Candel Therapeutics's price target?

Candel Therapeutics's price target, set by 6 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $5.36.

How does Candel Therapeutics stock forecast compare to its benchmarks?

Candel Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Candel Therapeutics over the past three months?

  • June 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Candel Therapeutics’s EPS forecast?

Candel Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.35, marking a -22.41% decrease from the reported $-1.74 in 2024. Estimates for the following years are.

What is Candel Therapeutics’s revenue forecast?

Candel Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4.35M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for.

What is Candel Therapeutics’s net income forecast?

Candel Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-39.063M, representing a 0% decrease from the reported $0 in 2024. Projections indicate .